Menu
VJHemOnc Podcast
Podcast image
iwAL 2023 Session III: The relevance of TP53 mutation in AML
9 mins; September 29, 2023
iwAL 2023 Session III: The relevance of TP53 mutation in AML
9 mins; September 29, 2023
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
28 mins; September 22, 2023
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
28 mins; September 22, 2023
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
18 mins; September 15, 2023
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
18 mins; September 15, 2023
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
10 mins; September 08, 2023
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
10 mins; September 08, 2023
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
9 mins; August 23, 2023
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
9 mins; August 23, 2023
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
10 mins; August 16, 2023
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
10 mins; August 16, 2023
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
8 mins; August 10, 2023
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
8 mins; August 10, 2023
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
7 mins; August 03, 2023
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
7 mins; August 03, 2023
Overcoming barriers to CAR-T therapy: improving access and cost
11 mins; July 27, 2023
Overcoming barriers to CAR-T therapy: improving access and cost
11 mins; July 27, 2023
The importance of addressing quality of life and improving symptom management in MPNs
6 mins; July 19, 2023
The importance of addressing quality of life and improving symptom management in MPNs
6 mins; July 19, 2023
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
8 mins; July 11, 2023
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
8 mins; July 11, 2023
Hemophilia: the current standard of care and the value of novel gene therapies
6 mins; July 05, 2023
Hemophilia: the current standard of care and the value of novel gene therapies
6 mins; July 05, 2023
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
14 mins; June 29, 2023
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
14 mins; June 29, 2023
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
8 mins; June 22, 2023
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
8 mins; June 22, 2023
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
16 mins; June 16, 2023
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
16 mins; June 16, 2023
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
12 mins; June 07, 2023
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
12 mins; June 07, 2023
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
11 mins; May 31, 2023
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
11 mins; May 31, 2023
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
11 mins; May 24, 2023
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
11 mins; May 24, 2023
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
14 mins; May 18, 2023
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
14 mins; May 18, 2023
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
15 mins; May 11, 2023
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
15 mins; May 11, 2023
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
11 mins; May 02, 2023
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
10 mins; May 02, 2023
The current role of stem cell transplantation in MPNs & how this may change with novel agents
9 mins; April 27, 2023
The current role of stem cell transplantation in MPNs & how this may change with novel agents
9 mins; April 27, 2023
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
11 mins; April 19, 2023
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
11 mins; April 19, 2023
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
13 mins; April 12, 2023
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
13 mins; April 12, 2023
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
15 mins; April 05, 2023
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
15 mins; April 05, 2023
Insights into the changing role of chemotherapy in lymphoma
7 mins; March 31, 2023
Insights into the changing role of chemotherapy in lymphoma
7 mins; March 31, 2023
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
44 mins; March 24, 2023
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
44 mins; March 24, 2023
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
13 mins; March 16, 2023
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
13 mins; March 16, 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
9 mins; March 10, 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
9 mins; March 10, 2023
The current status of CAR-T therapy in CLL and challenges in this space
8 mins; March 03, 2023
The current status of CAR-T therapy in CLL and challenges in this space
8 mins; March 03, 2023
Managing and treating GvHD and other post-transplant complications
9 mins; February 23, 2023
Managing and treating GvHD and other post-transplant complications
9 mins; February 23, 2023
The role of MRD in multiple myeloma
8 mins; February 14, 2023
The role of MRD in multiple myeloma
8 mins; February 14, 2023
Novel immune therapies in MDS and challenges in this space
7 mins; February 07, 2023
Novel immune therapies in MDS and challenges in this space
7 mins; February 07, 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
11 mins; February 02, 2023
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
11 mins; February 02, 2023
MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
14 mins; January 26, 2023
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
14 mins; January 26, 2023
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
8 mins; January 20, 2023
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
8 mins; January 20, 2023
The importance of CD47 in MDS and other targets of interest
7 mins; January 17, 2023
The importance of CD47 in MDS and other targets of interest
7 mins; January 17, 2023
CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy
7 mins; January 09, 2023
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
7 mins; January 09, 2023
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
14 mins; January 03, 2023
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
14 mins; January 03, 2023
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
14 mins; December 21, 2022
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
14 mins; December 21, 2022
iwNHL Session V: novel therapies in NHL – the role of ADCs
12 mins; December 16, 2022
iwNHL Session V: Novel therapies in NHL - the role of ADCs
12 mins; December 16, 2022
iwAL 2022 Session V: mechanisms of resistance to targeted therapies in AML
12 mins; December 06, 2022
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
12 mins; December 06, 2022
The importance of genomic testing in CLL and its role in clinical decision-making
10 mins; December 02, 2022
The importance of genomic testing in CLL and its role in clinical decision-making
10 mins; December 02, 2022
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
17 mins; November 30, 2022
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
17 mins; November 30, 2022
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
11 mins; November 25, 2022
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
11 mins; November 25, 2022
iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
16 mins; November 22, 2022
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
16 mins; November 22, 2022
iwNHL Session III: exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
11 mins; November 18, 2022
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
11 mins; November 18, 2022
iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
12 mins; November 16, 2022
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
12 mins; November 16, 2022
Recent updates in CML: treatment strategies, clinical trials, and novel agents
15 mins; November 11, 2022
Recent updates in CML: treatment strategies, clinical trials, and novel agents
15 mins; November 11, 2022
iwNHL Session II: understanding and harnessing the immune microenvironment against lymphoma
13 mins; November 09, 2022
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
13 mins; November 09, 2022
Click here to see more
Useful pages

Apply to teach

Reviews

Help & FAQs

Blog

Spanish Podcast

French Podcast

Italian Podcast

About Us

Contact Us

Terms & Privacy

Find a tutor

Arabic tutors

Chinese tutors

Dutch tutors

English tutors

French tutors

German tutors

Greek tutors

Italian tutors

Japanese tutors

Korean tutors

Portuguese tutors

Romanian tutors

Russian tutors

Spanish tutors

Swedish tutors

Thai tutors

More languages soon!

Languages

Learn Arabic

Learn Chinese

Learn Dutch

Learn English

Learn French

Learn German

Learn Greek

Learn Italian

Learn Japanese

Learn Korean

Learn Portuguese

Learn Romanian

Learn Russian

Learn Spanish

Learn Swedish

Learn Thai

© 2026 LanguaTalk, All Rights Reserved